Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: Six patients were still responding at 7.5 months of follow-up, according to research presented in San Diego at the annual meeting of the American Society of Hematology (ASH). The highest trial dose was discontinued due to toxicity. Nearly a third of trial patients developed serious infections and other side effects included nerve damage and liver failure. Amgen said AMG420, which targets a protein linked to multiple myeloma known as BCMA, has been given fast track status by the U.S. Food and Drug Administration. "Based on these data, we plan to open an expanded trial," David Reese, Amgen's head of research and development, said in an interview. "We want to begin exploring quickly enrollment in earlier lines of therapy." Amgen's pipeline of bispecific antibodies, which are designed to attach to a cancer cell and an immune cell, bringing them together so the body's immune system can kill the cancer, are a cornerstone of the biotech company's oncology research. Other companies are exploring different ways to attack the same BCMA target, including bluebird bio Inc, Celgene Corp and Johnson & Johnson. Earlier at the ASH meeting, bluebird and Celgene presented early trial data showing that experimental cell therapy bb21217 induced responses in 10 out of 12 heavily pre-treated myeloma patients. Bb21217 is a next-generation version of bb2121, the companies' more advanced, but still experimental therapy in a class called CAR-T that requires harvesting a patient's own disease-fighting T-cells, modifying them in a laboratory so they target specific proteins on cancer cells and infusing them back into the patient. The manufacturing process for bb21217 is designed to improve the persistence of the altered cells. J&J, which licensed BCMA-directed CAR-T LCAR-B38M from a unit of China-based GenScript Biotech Corp, on Monday presented updated results from a Chinese study of the cell therapy in 57 previously treated myeloma patients. It showed that 88 percent of patients responded to the treatment, and 74 percent achieved remission. J&J is currently enrolling patients in an international study aimed at validating those findings. Amgen has suggested the "off the shelf" nature of its antibody platform could be an advantage from both a clinical and commercial standpoint, but oncologists say more data is needed. Trial patients are hospitalized for their first cycle of AMG420, after which they receive the drug by continuous 24-hour infusion for four weeks, followed by two weeks off therapy, for up to 10 cycles. Amgen has another BCMA-targeting antibody that lasts longer in the body, requiring less frequent infusions, but that research is at an earlier stage. In the current study, 42 patients with multiple myeloma that worsened after at least two prior treatments were given AMG420 at varying doses. A total of 13 patients responded to the treatment, including seven who achieved remission. Of the 20 patients with serious adverse events, 17 required hospitalization and four had prolonged hospitalization.

Output: Amgen antibody shows promise in myeloma trial, gets FDA fast track.

Input: Consider Input: The FDA said it received 85 reports from patients who switched from Wellbutrin XL to Teva Pharmaceutical Industries Ltd and Impax Laboratories Inc's cheaper generic, including 78 who said they slipped back into depression. Other patients reported new or worsening side effects, including headaches, fatigue, anxiety and digestion issues. "The question is whether the reported lack of efficacy and/or new onset side effects in these patients who switched suggest a problem with the generic product ... or have some other explanation," the FDA said in a statement on its website. Agency scientists reviewed 300-milligram versions of the two drugs, which both use once-a-day formulations of the chemical bupropion, and found the data did not show that the problems stemmed from any differences between the two drugs. One factor that could account for the reported problems is the natural recurrence of depression, which can happen despite treatment, the FDA said. Half of the patients who went back on the name-brand drug said they improved, the agency said, adding that it would continue to monitor the issue. FDA officials received the reports during the first half of 2007. Teva and Impax's version of Wellbutrin was approved in 2006. Watson Pharmaceuticals Inc also makes a 300-mg XL version of bupropion, though it was not part of the FDA's review. GlaxoSmithKline makes other versions of Wellbutrin that face generic competition. Total sales of Wellbutrin slipped 37 percent last year in the face of generic competition, the company has reported. The drugmaker could not comment on the FDA's conclusion because it did not have access to the data used but is pleased the agency would continue its monitoring, GlaxoSmithKline spokeswoman Mary Anne Rhyne said. Teva spokeswoman Denise Bradley said the company would issue a statement later. Shares of GlaxoSmithKline rose 39 cents to $42.47 on the New York Stock Exchange. Teva rose 65 cents, or 1.4 percent, to $46.67 on Nasdaq.

Output: FDA says generic Wellbutrin OK despite reports.

Input: Consider Input: We would have liked to have seen a little more information on costs, but we are glad that costs are mentioned up high. In the third sentence, the story says, "The surgery necessary to allow deep brain stimulation is extremely expensive" Later it says, "The cost of the surgery is about $50,000". It would have been interesting to note whether deep brain stimulation is covered by Medicare or any insurance companies for treatment of any disorders, including Parkinson's. The story attempts to quantify the benefits in both relative and absolute terms, but it leaves readers confused because of the shifting nature of the study cohort. It looks as if the study started with 17 patients but then later it says that the study looked at 14 patients. It says, "The researchers found that 18 percent of patients went into remission after 24 weeks, 36 percent (of 14 patients) after one year. After two years, of the 12 patients still in the study, seven patients (58 percent) were in remission." The change in the number appears to be because the researchers stopped doing the deep brain stimulation on three patients, a fact that is not fully explored in the story. This all would have been more easily explained and less confusing if the story had just stuck with the absolute numbers. If you try to do the math on 18 percent of 14 patients, for example, you get 2.52 patients. Was it two patients? Was it three? Why not just tell readers x number out of x number? There's just one line in the story about harms: "Patients didn't suffer from side effects, she noted." The story also says, "The workings of deep brain stimulation as a whole are a mystery, although Mayberg said it may work by changing the brain's rhythms." If how it works is a mystery, we think a little more space should have been devoted to potential harms. There were a total of 8 adverse events related to either the surgery or the device, two of which were deemed serious (infection). The story misses these events entirely. The story cautiously explains the evidence and the reasons for the optimism around the evidence. It shows that the study is in a very small group of people just 17. But it also shows that the study followed them for two years. However, while providing some of the important caveats, it fails to note that there were no control subjects. While the results may appear encouraging, they are by no means definitive without a control group. Nonetheless, we'll give the story the benefit of the doubt on this one. The story does not engage in disease mongering and makes it clear that it is "too early to know for sure if the treatment is appropriate to be used for any kind of depression." The story says that the St. Jude Medical Neuromodulation company "provided consulting fees to Mayberg and some of the other study authors" and "is currently recruiting patients for a study that could pave the way for its approval as a treatment for depression." The story also quotesSamuel James Collier, M.D., assistant professor of psychiatry, University of Texas Southwestern Medical Center at Austin, who provides a welcome dose of skepticism to the story, saying "Medications and ECT electroconvulsive therapy are clearly safer, better tolerated, and do not embody a large surgical risk. I can't think of a scenario where deep brain stimulation would be considered even remotely before medications and ECT were exhausted." The story alludes to other treatment options, including medications and electroconvulsive therapy, and it quotes an outside expert saying that these are preferable. The story makes it clear that the treatment is widely available, saying, "Deep brain stimulation has been around for more than 20 yearsand is commonly used to treat Parkinson's disease." There are no claims of novelty made in the story. The story does not rely on this press release from Emory University.
Output: Study Looks at Deep Brain Stimulation in Bipolar Patients